The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty

Chris Skedgel; Ron Goeree; Sue Pleasance; Kara Thompson; Bernie O'Brien; David Anderson

doi:10.2106/JBJS.F.00092

The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty

Chris Skedgel, Ron Goeree, Sue Pleasance, Kara Thompson, Bernie O'Brien, David Anderson

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

Although the risk of thromboembolism after total hip arthroplasty continues beyond hospital discharge, the cost-effectiveness of extending prophylaxis beyond hospitalization is unclear. We compared the cost-effectiveness of an extended duration of antithrombotic prophylaxis following total hip arthroplasty, with use of low-molecular-weight heparin or warfarin administered for twenty-eight days beyond hospital discharge, in terms of incremental cost per quality-adjusted life year gained.

Original language	English
Pages (from-to)	819-828
Number of pages	10
Journal	The Journal of Bone and Joint Surgery (American)
Volume	89
Issue number	4
DOIs	https://doi.org/10.2106/JBJS.F.00092
Publication status	Published - Apr 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anticoagulants
Arthroplasty, Replacement, Hip
Cost-Benefit Analysis
Heparin, Low-Molecular-Weight
Humans
Thromboembolism
Time Factors
Warfarin

Access to Document

10.2106/JBJS.F.00092

Cite this

@article{e0e4313392fd4817b007412be6993684,

title = "The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty",

abstract = "Although the risk of thromboembolism after total hip arthroplasty continues beyond hospital discharge, the cost-effectiveness of extending prophylaxis beyond hospitalization is unclear. We compared the cost-effectiveness of an extended duration of antithrombotic prophylaxis following total hip arthroplasty, with use of low-molecular-weight heparin or warfarin administered for twenty-eight days beyond hospital discharge, in terms of incremental cost per quality-adjusted life year gained.",

keywords = "Anticoagulants, Arthroplasty, Replacement, Hip, Cost-Benefit Analysis, Heparin, Low-Molecular-Weight, Humans, Thromboembolism, Time Factors, Warfarin",

author = "Chris Skedgel and Ron Goeree and Sue Pleasance and Kara Thompson and Bernie O'Brien and David Anderson",

year = "2007",

month = apr,

doi = "10.2106/JBJS.F.00092",

language = "English",

volume = "89",

pages = "819--828",

journal = "The Journal of Bone and Joint Surgery (American)",

issn = "0021-9355",

publisher = "Journal of Bone and Joint Surgery Inc.",

number = "4",

}

TY - JOUR

T1 - The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty

AU - Skedgel, Chris

AU - Goeree, Ron

AU - Pleasance, Sue

AU - Thompson, Kara

AU - O'Brien, Bernie

AU - Anderson, David

PY - 2007/4

Y1 - 2007/4

N2 - Although the risk of thromboembolism after total hip arthroplasty continues beyond hospital discharge, the cost-effectiveness of extending prophylaxis beyond hospitalization is unclear. We compared the cost-effectiveness of an extended duration of antithrombotic prophylaxis following total hip arthroplasty, with use of low-molecular-weight heparin or warfarin administered for twenty-eight days beyond hospital discharge, in terms of incremental cost per quality-adjusted life year gained.

AB - Although the risk of thromboembolism after total hip arthroplasty continues beyond hospital discharge, the cost-effectiveness of extending prophylaxis beyond hospitalization is unclear. We compared the cost-effectiveness of an extended duration of antithrombotic prophylaxis following total hip arthroplasty, with use of low-molecular-weight heparin or warfarin administered for twenty-eight days beyond hospital discharge, in terms of incremental cost per quality-adjusted life year gained.

KW - Anticoagulants

KW - Arthroplasty, Replacement, Hip

KW - Cost-Benefit Analysis

KW - Heparin, Low-Molecular-Weight

KW - Humans

KW - Thromboembolism

KW - Time Factors

KW - Warfarin

U2 - 10.2106/JBJS.F.00092

DO - 10.2106/JBJS.F.00092

M3 - Article

C2 - 17403806

SN - 0021-9355

VL - 89

SP - 819

EP - 828

JO - The Journal of Bone and Joint Surgery (American)

JF - The Journal of Bone and Joint Surgery (American)

IS - 4

ER -